Biopharma buyouts still pricey
A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.
Biopharma shares keep riding the Covid wave
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
Mapping the transatlantic divide for biotech flotations
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Hints of moderation emerge in biotech venture funding
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Another huge quarter for biotech flotations
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
For a quick exit, head to the stock market
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
